Alcidion Group Ltd (ASX: ALC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Alcidion Group Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $61.75 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 1.34 billion
Earnings per share -0.004
Dividend per share N/A
Year To Date Return -38.67%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Alcidion Group Ltd (ASX: ALC)
    Latest News

    ASX share price on watch represented by man looking through magnifying glass
    Small Cap Shares

    3 exciting small cap ASX shares to watch

    Alcidion Group Ltd (ASX:ALC) and these exciting small cap ASX shares could be worthy of a spot on your watchlist...

    Read more »

    A young boy sits on his dad's shoulders while both flex their muscles.
    Share Market News

    3 ASX growth stocks running higher this week

    While classic growth stocks such as Afterpay Ltd (ASX: APT) are going sideways, here are 3 ASX growth shares surging…

    Read more »

    A happy woman at her laptop punches the air, indicating a rising share price
    Share Market News

    ASX tech shares roar higher, puts ASX 200 index in the shade

    Alcidion and Whispir shares roar higher, Costa wilts.

    Read more »

    white arrow dropping down representing the 10 most shorted shares on the ASX
    Healthcare Shares

    Why the Alcidion (ASX:ALC) share price is falling again today

    The Alcidion Group Ltd (ASX: ALC) share price has continued its negative run this week and is again backtracking today.…

    Read more »

    falling healthcare asx share price Mesoblast capital raising
    Healthcare Shares

    Alcidion (ASX:ALC) share price slumps despite 'strong growth'

    The Alcidion Group (ASX: ALC) share price is on the slide today following the company's release of its Q3 results.…

    Read more »

    ASX shares profit upgrade chart showing growth
    Share Market News

    Why the Alcidion (ASX:ALC) share price is up 32% this month

    The Alcidion share price is has had an amazing month as multiple catalysts have driven its shares higher. We take…

    Read more »

    Young doctor raising arms in air with hands in fists celebrating a new development
    Healthcare Shares

    Why the Alcidion (ASX:ALC) share price just hit an all-time high

    The Alcidion Group Ltd (ASX: ALC) share price just hit an all-time high as the company made three separate, material…

    Read more »

    pause in medical asx share price represented by doctor holding hand up in stop motion
    Capital Raising

    Alcidion (ASX:ALC) shares are in a trading halt. Here's why.

    Alcidion Group Ltd (ASX: ALC) shares are in a trading halt ahead of a planned acquisition and capital raise annnouncement…

    Read more »

    asx share price on watch represented by investor looking through magnifying glass
    Small Cap Shares

    4 exciting small cap ASX shares to watch

    Nitro Software Ltd (ASX:NTO) and these exciting small cap ASX shares could be worthy of a spot on your watchlist...

    Read more »

    high share price
    Share Gainers

    Why Alcidion, GrainCorp, Premier Investments, & Xero are storming higher

    Premier Investments Limited (ASX:PMV) and Xero Limited (ASX:XRO) are two of four ASX shares storming higher on Wednesday...

    Read more »

    Share Market News

    Why the Alcidion (ASX:ALC) share price is surging 5% higher

    The Alcidion Group Ltd (ASX:ALC) share price is pushing higher on Wednesday after announcing a new contract win in the…

    Read more »

    rising asx share price represented by investor with look of happy surprise
    Share Gainers

    Why these ASX shares are breaking out into record highs

    While the ASX 200 might be chopping back and forth, here are some ASX shares breaking into new record territory.

    Read more »

    Frequently Asked Questions

    No, Alcidion does not pay dividends at this time.

    Alcidion listed on the ASX on 24 June 2011.

    ALC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Alcidion Group Ltd

    Alcidion Group Ltd (ASX: ALC) is a provider of intelligent informatics software for the healthcare sector.

    The company builds, sells, delivers, runs, and supports solutions for healthcare providers. These include clinical, analytical, managerial, and administrative systems.

    Its products include its Miya suite, a Fast Healthcare Interoperability Resources (FHIR) system that allows comprehensive healthcare data to be exchanged between different computer systems.  Other products include Smartpage and Patientrack software.

    Alcidion derives the majority of its revenue from its Australia/New Zealand segment and also has a presence in the United Kingdom.

    ALC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    23 Apr 2024 $0.05 $0.00 0.00% 1,007,217 $0.05 $0.05 $0.04
    22 Apr 2024 $0.05 $0.00 0.00% 1,119,092 $0.05 $0.05 $0.05
    19 Apr 2024 $0.05 $0.00 0.00% 308,681 $0.05 $0.05 $0.05
    18 Apr 2024 $0.05 $0.00 0.00% 2,729,213 $0.04 $0.05 $0.04
    17 Apr 2024 $0.04 $0.00 0.00% 559,278 $0.04 $0.05 $0.04
    16 Apr 2024 $0.04 $0.00 0.00% 198,223 $0.04 $0.05 $0.04
    15 Apr 2024 $0.04 $0.00 0.00% 415,242 $0.05 $0.05 $0.04
    12 Apr 2024 $0.05 $0.00 0.00% 584,170 $0.04 $0.05 $0.04
    11 Apr 2024 $0.04 $0.00 0.00% 798,378 $0.05 $0.05 $0.04
    10 Apr 2024 $0.05 $0.00 0.00% 1,630,771 $0.05 $0.05 $0.05
    09 Apr 2024 $0.05 $0.00 0.00% 2,605,790 $0.05 $0.05 $0.05
    08 Apr 2024 $0.05 $0.00 0.00% 479,643 $0.05 $0.05 $0.05
    05 Apr 2024 $0.05 $0.00 0.00% 470,771 $0.05 $0.05 $0.05
    04 Apr 2024 $0.05 $0.00 0.00% 217,902 $0.05 $0.05 $0.05
    03 Apr 2024 $0.05 $0.00 0.00% 279,323 $0.05 $0.05 $0.05
    02 Apr 2024 $0.05 $0.00 0.00% 2,597,262 $0.05 $0.05 $0.05
    28 Mar 2024 $0.05 $0.00 0.00% 275,881 $0.05 $0.05 $0.05
    27 Mar 2024 $0.05 $0.00 0.00% 206,294 $0.05 $0.05 $0.05
    26 Mar 2024 $0.05 $0.00 0.00% 279,304 $0.05 $0.05 $0.05

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    05 Sep 2023 Victoria Weekes Buy 100,000 $12,000
    On-market trade.
    09 May 2023 Daniel Sharp Buy 210,000 $20,230
    On-market trade.
    05 May 2023 Daniel Sharp Buy 590,000 $55,191
    On-market trade.
    03 May 2023 Rebecca Wilson Buy 250,000 $24,250
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Rebecca Wilson Non-Executive DirectorNon-Executive Chairman Jul 2017
    Ms Wilson is an experienced company director and Board advisor in Australia, UK and US and has more than 25 years of experience working within the healthcare, technology and life science sectors. She provides advice on complex stakeholder communication, issues management, investor and corporate relations, and business strategy to private and public companies, corporations, governments, and asset managers. She has mature governance and risk management experience.
    Mr Simon Chamberlain Non-Executive Director Jul 2019
    Mr Chamberlain is an accomplished executive and business leader, with more than 20 years experience in executive roles at companies including Experian (LON: EXPN), Medibank Private (ASX: MPL), Qantas (ASX:QAN) and MedAdvisor (ASX:MDR). He is currently the Chief Revenue Officer at the high-growth, techenabled residential services business, Detector Inspector, where he runs the sales, marketing, support and strategy functions. Simon has a proven track record for strategic success and commercial growth across a range of industries and markets. Simon led Qantas entrance into the online hotels business, establishing a profitable, high growth new division. At Medibank, Simon had responsibility across customer channels, data and customer experience. Gaining a better understanding of the complex challenges facing the wider health system led to Simons role leading strategy for MedAdvisor, where he supported the global expansion of its health technology business. Simon brings a valuable international perspective and global network to the Alcidion Board, holding executive roles across the US and the UK, where he was a key part of the executive team that sold the Australian start-up, Hitwise, to Experian in 2007. He is also a member of risk committee.
    Ms Victoria Weekes Non-Executive Director Sep 2021
    Ms Weekes is an non-executive director with experience across a diverse range of industries built on a successful executive career in investment markets and financial services. Victorias 30 years of experience in the finance and banking sector includes Csuite roles as a Managing Director at Citigroup and Executive General Manager at Westpac. As the immediate past Chair of the Sydney Local Health District, Victoria has a deep understanding of the healthcare sector where she served as Chair of its Education & Research Committee and Deputy Chair. Recognised for her specialist expertise in risk management and regulation having led organisations through strategic issue management and transformational change, Victoria is Deputy Chair of the ASIC Markets Disciplinary Panel, immediate past Chair of the NSW Treasury Audit & Risk Committee and President of the Financial Services Institute of Australasia (FINSIA). Until recently Victoria was the Deputy Chair of St George Community Housing, NSWs largest non-government community and affordable housing provider and a member of the Council of the State Library of NSW. She is the chairman of risk committee.
    Ms Katrina (Kate) Elizabeth Doyle (Quirke) Chief Executive OfficerExecutive DirectorManaging Director Jul 2018
    Ms Doyle has been CEO of Alcidion since 2018, prior to which she was CEO of MKM Health until it was acquired by Alcidion. She has been involved in large systems procurements and implementations of healthcare information technology across Australia, United Kingdom, New Zealand and Southeast Asia. Her background involves holding leading management roles at some of the largest healthcare software firms where she has had an impact on strategic product direction across
    the health sector and believes astute application of information technology will support the transformation of healthcare delivery worldwide.
    Mr Daniel Sharp Non-Executive Director Sep 2021
    Originally commencing his career as a lawyer,Mr Sharp has over 25 years senior executive experience in investment banking and corporate finance. From 2012-2020, Daniel was an Executive Director of Corporate Finance at Canaccord Genuity where he led dozens of equity capital market transactions and corporate finance advisory projects across the healthcare, life sciences, technologies, financial services and general industrials sectors. Prior to his executive role at Canaccord, Daniel headed the corporate finance division at two of Australias leading independent Investment Banking/Stockbroking firms. Daniel has managed the IPOs, capital raisings and corporate advisory activities for many successful ASX listed companies in the healthcare, technologies and general industrials sectors. He is closely connected to strong networks of institutional, family office and high net worth investors both in Australia and overseas. he is also a member of risk committee.
    Ms Melanie Jaye Leydin Company Secretary Mar 2019
    -
    Melanie Jaye Leydin Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    J P Morgan Nominees Australia Pty Limited 139,803,795 11.02%
    Mr Malcolm Pradhan 134,582,403 10.61%
    Mr Raymond Howard Blight 75,801,020 5.98%
    Citicorp Nominees Pty Limited 58,449,895 4.61%
    Rewmicman Pty Ltd <Smallman Family A/C> 29,810,441 2.35%
    Mrs Katrina Elizabeth Doyle 27,793,199 2.19%
    Caledonia Nominees Pty Ltd <Caledonia A/C> 19,976,377 1.58%
    MNMD Pty Ltd <Quirke Super Fund A/C> 18,668,086 1.47%
    Rangiora-London Pty Limited <Rangiora-London A/C> 9,800,000 0.77%
    Sandhurst Trustees Ltd <Cyan C3G Fund A/C> 9,469,114 0.75%
    Bnp Paribas Noms Pty Ltd <Drp> 9,129,104 0.72%
    Hsbc Custody Nominees (Australia) Limited 8,651,688 0.68%
    Mr Dean Anthony Mackenzie 8,270,080 0.65%
    Mr Paul John Van Dyk 7,277,866 0.57%
    Isle Of Wight Pty Limited <Mackinnon Family A/C> 6,980,867 0.55%
    Emerald Shares Pty Limited <Emerald Unit A/C> 6,850,000 0.54%
    Hudson Retirement Pty Ltd <Seagulls Super A/C> 6,524,244 0.51%
    Mr Vivek Ramakrishnan + Miss Nisha Srinivasan 6,033,121 0.48%
    Superhero Securities Limited <Client A/C> 5,602,157 0.44%
    Beale & Co Pty Ltd 5,066,134 0.40%

    Profile

    since

    Note